Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Androgen Effects on the Reproductive Neuroendocrine Axis
NCT06450405 · University of California, San Diego · PHASE4 · terminated · last registry update 2025-07-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study sponsor terminated the grant funding.” | – | Registry record, University of California, San Diego |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-16Results posted on the registry: Dana-Farber Cancer Institute, Testosterone Cypionate 100 MG/ML + Placebo (NCT03716739)
- 2026-07-02Results posted on the registry: Washington University School of Medicine, Androgen deprivation therapy (NCT05628363)
- 2026-05-07Results posted on the registry: Brigham and Women's Hospital, Testosterone Undecanoate (NCT03576001)
- 2026-05-07Also stopped (terminated): University of Southern California, Oxandrolone + Placebo (NCT03091075)
- 2026-03-27Also stopped (suspended): George F. Hatch, Oxandrolone + Placebo (NCT05893069)
- 2025-12-23Results posted on the registry: VA Office of Research and Development, Testosterone gel 1.62% + Placebo (NCT03887936)
- 2025-09-23Also stopped (withdrawn): OHSU Knight Cancer Institute, Gonadotropin Releasing Hormone Agonists and Antagonists + Bicalutamide (NCT06528210)
- 2025-08-05Also stopped (terminated): The University of Queensland, Danazol + Placebo (NCT04638517)
- 2025-07-31Phase 3 first posted: Jaeb Center for Health Research, Atropine + Placebo Eyedrops (NCT07095894)
- 2025-07-22Also stopped (withdrawn): University of Nebraska, Bicalutamide (NCT06501911)
- 2025-03-24Results posted on the registry: Imperial College London, a drug against AR (NCT04049747)
- 2025-03-14Results posted on the registry: Endo USA Inc., a Keenova Therapeutics Company, Aveed Injectable Product + Fortesta (NCT04456296)
- 2025-03-07Phase 3 first posted: Singapore National Eye Centre, a drug against AR (NCT06863675)
- 2025-02-13Results posted on the registry: Kimberly Myer, Nestorone® /testosterone gel + Testosterone only gel (NCT02432261)
- 2025-01-13Also stopped (withdrawn): University of California, San Diego, Testosterone Cyp 200Mg/Ml Inj (in Oil) + Letrozole (NCT04321551)
- 2024-12-13Results posted on the registry: Peter Kovacs MD, Follitropin Alfa + Follitropin delta (NCT05103228)
- 2024-11-14Phase 3 first posted: Halozyme Therapeutics, Testosterone enanthate (NCT06689085)
- 2024-10-21Phase 3 first posted: Emory University, Abiraterone Acetate + Bicalutamide (NCT06650579)
- 2024-10-16Results posted on the registry: RTOG Foundation, Inc., Enzalutamide + Bicalutamide (NCT03809000)
- 2024-08-26Results posted on the registry: Palo Alto Veterans Institute for Research, Testim, 1% testosterone gel (NCT00645658)
- 2024-08-09Also stopped (terminated): University Medical Center Groningen, AndroGel (NCT05156606)
- 2024-07-29Phase 3 first posted: Johns Hopkins University, Cysview (NCT06525571)
- 2024-07-23Also stopped (terminated): Icahn School of Medicine at Mount Sinai, Danazol (NCT00953771)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision